Janssen Biotech Inc. is hoping to soon contain a new entry in the increasingly competitive market for psoriasis treatments.
The Horsham company,a division of Johnson & Johnson (NYSE: JNJ), filed a biologics license application [BLA) with Food and Drug Administration seeking approval for guselkumab as a treatment for adults with moderate-to-severe plaque psoriasis.
Psoriasis is a chronic, and autoimmune inflammatory disorder that results in the overproduction of skin cells. An estimated 125 million people…
Source: bizjournals.com